Castle Biosciences (CSTL) Competitors $20.42 +0.07 (+0.34%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CSTL vs. ADUS, VCYT, PACS, WGS, LFST, ARDT, PGNY, NHC, GRAL, and TDOCShould you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Addus HomeCare (ADUS), Veracyte (VCYT), PACS Group (PACS), GeneDx (WGS), LifeStance Health Group (LFST), Ardent Health (ARDT), Progyny (PGNY), National HealthCare (NHC), GRAIL (GRAL), and Teladoc Health (TDOC). These companies are all part of the "healthcare" industry. Castle Biosciences vs. Its Competitors Addus HomeCare Veracyte PACS Group GeneDx LifeStance Health Group Ardent Health Progyny National HealthCare GRAIL Teladoc Health Castle Biosciences (NASDAQ:CSTL) and Addus HomeCare (NASDAQ:ADUS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations. Do institutionals & insiders hold more shares of CSTL or ADUS? 92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 95.4% of Addus HomeCare shares are owned by institutional investors. 7.2% of Castle Biosciences shares are owned by insiders. Comparatively, 4.6% of Addus HomeCare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, CSTL or ADUS? Addus HomeCare has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCastle Biosciences$332.07M1.78$18.25M-$0.19-107.47Addus HomeCare$1.15B1.84$73.60M$4.4326.00 Do analysts rate CSTL or ADUS? Castle Biosciences currently has a consensus target price of $37.00, suggesting a potential upside of 81.19%. Addus HomeCare has a consensus target price of $142.57, suggesting a potential upside of 23.77%. Given Castle Biosciences' higher possible upside, equities analysts plainly believe Castle Biosciences is more favorable than Addus HomeCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Castle Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Addus HomeCare 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Is CSTL or ADUS more profitable? Addus HomeCare has a net margin of 6.52% compared to Castle Biosciences' net margin of -1.46%. Addus HomeCare's return on equity of 9.23% beat Castle Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Castle Biosciences-1.46% 3.41% 2.95% Addus HomeCare 6.52%9.23%6.96% Which has more risk & volatility, CSTL or ADUS? Castle Biosciences has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Addus HomeCare has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Does the media refer more to CSTL or ADUS? In the previous week, Addus HomeCare had 7 more articles in the media than Castle Biosciences. MarketBeat recorded 9 mentions for Addus HomeCare and 2 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.94 beat Addus HomeCare's score of 0.42 indicating that Castle Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Addus HomeCare 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAddus HomeCare beats Castle Biosciences on 12 of the 17 factors compared between the two stocks. Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSTL vs. The Competition Export to ExcelMetricCastle BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$587.55M$2.84B$5.45B$8.90BDividend YieldN/A2.70%5.36%4.14%P/E Ratio-107.4721.0226.3419.65Price / Sales1.78260.80406.69110.21Price / Cash20.6841.2925.8827.49Price / Book1.257.247.925.42Net Income$18.25M-$55.05M$3.15B$248.34M7 Day Performance8.33%1.83%2.20%2.41%1 Month Performance27.86%6.06%4.39%4.80%1 Year Performance-6.20%0.66%32.26%17.50% Castle Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSTLCastle Biosciences2.6728 of 5 stars$20.42+0.3%$37.00+81.2%-6.5%$587.55M$332.07M-107.47540ADUSAddus HomeCare4.7402 of 5 stars$113.01-0.7%$142.57+26.2%-0.9%$2.09B$1.15B25.5149,703Positive NewsAnalyst UpgradeVCYTVeracyte3.4626 of 5 stars$26.71+1.2%$40.90+53.1%+26.3%$2.07B$445.76M65.15790Analyst DowngradePACSPACS Group2.7325 of 5 stars$12.77-3.1%$34.29+168.5%-55.9%$2.01B$3.11B0.0032,433WGSGeneDx1.9027 of 5 stars$79.71+19.0%$86.75+8.8%+248.5%$1.91B$305.45M73.631,200News CoverageAnalyst ForecastGap DownHigh Trading VolumeLFSTLifeStance Health Group2.4056 of 5 stars$4.96+2.7%$8.50+71.4%+4.9%$1.88B$1.25B0.0010,218ARDTArdent Health3.4051 of 5 stars$12.94-0.8%$20.67+59.7%N/A$1.87B$5.97B7.9524,900PGNYProgyny1.0604 of 5 stars$20.79-0.9%$23.45+12.8%-23.4%$1.80B$1.17B39.58310NHCNational HealthCareN/A$106.43+1.5%N/A-0.2%$1.65B$1.37B13.3412,400GRALGRAIL0.6711 of 5 stars$43.07-5.6%$31.50-26.9%N/A$1.64B$125.60M0.001,360Gap DownTDOCTeladoc Health2.0875 of 5 stars$7.90+14.5%$9.60+21.5%-13.8%$1.21B$2.57B-1.335,500Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Addus HomeCare Alternatives Veracyte Alternatives PACS Group Alternatives GeneDx Alternatives LifeStance Health Group Alternatives Ardent Health Alternatives Progyny Alternatives National HealthCare Alternatives GRAIL Alternatives Teladoc Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSTL) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredConsumer apocalypse imminent (7 ominous red flags)The #1 Gold play right now (not a miner, ETF, or bullion) Gold is up 237% since 2008... but one gold invest...Stansberry Research | Sponsored“Trump’s 24-Hour Profit Windows” revealedTrading legend Larry Benedict has discovered a repeating surge of $240 billion (and more)... Flowing into a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CSTL Stock Alerts